Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis, December 2012
The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of established business and expertise gained from acquired companies.
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis.” The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.
The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:
This study is intended to provide industry leaders with a competitive benchmarking of the world’s top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and insight, critical to the development and implementation of an effective marketing and sales plan.
This report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global cardiovascular drug companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis.” The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.
The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:
- AstraZeneca
- Bristol-Myers Squibb
- Novartis
- Pfizer
- Sanofi
This study is intended to provide industry leaders with a competitive benchmarking of the world’s top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and insight, critical to the development and implementation of an effective marketing and sales plan.
This report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global cardiovascular drug companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business
1. EXECUTIVE SUMMARY
2. MARKET DEFINITION AND SCOPE
3. MARKET OPPORTUNITY
4. COMPETITIVE BENCHMARKING (FINANCIAL AND MARKET)
Company Profile on Following Parameters
Company Overview
Benchmarking (Financial & Market)
SWOT Analysis
Product Positioning
Marketing Strategy and Tactics
Corporate Strategy
5. COMPANY PROFILE ON ASTRAZENECA
6. COMPANY PROFILE ON BRISTOL-MYERS SQUIBB
7. COMPANY PROFILE ON NOVARTIS
8. COMPANY PROFILE ON PFIZER
9. COMPANY PROFILE ON SANOFI
2. MARKET DEFINITION AND SCOPE
3. MARKET OPPORTUNITY
4. COMPETITIVE BENCHMARKING (FINANCIAL AND MARKET)
Company Profile on Following Parameters
Company Overview
Benchmarking (Financial & Market)
SWOT Analysis
Product Positioning
Marketing Strategy and Tactics
Corporate Strategy
5. COMPANY PROFILE ON ASTRAZENECA
6. COMPANY PROFILE ON BRISTOL-MYERS SQUIBB
7. COMPANY PROFILE ON NOVARTIS
8. COMPANY PROFILE ON PFIZER
9. COMPANY PROFILE ON SANOFI
LIST OF FIGURES AND CHARTS
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for cardiovascular drug market
Figure 3.2: Global cardiovascular drug industry annual trend 2006-2011 (US $B)
Figure 3.3: Global cardiovascular drug industry regional trend 2006-2011 (US $B)
Figure 3.4: Global cardiovascular drug industry regional trend 2006-2011 (%)
Figure 3.5: Global cardiovascular drug industry segment trend 2006-2011 (US $B)
Figure 3.6: Global cardiovascular drug industry segment trend 2006-2011 (%)
Figure 3.7: Global cardiovascular drug industry opportunity by region
Figure 3.8: Global cardiovascular drug industry opportunity by segment
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five cardiovascular drug companies – financial benchmarking
Figure 4.2: Global top five cardiovascular drug companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
CHAPTER 5. Company Profile of AstraZeneca
Figure 5.1: AstraZeneca’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – AstraZeneca
Figure 5.3: Financial benchmarking AstraZeneca against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of AstraZeneca against Top Five best
Figure 5.5: Global industry revenue trend Vs AstraZeneca (2007-2011) in US $B
Figure 5.6: Global market share trend for AstraZeneca (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.12: European market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.15: AstraZeneca trend in R&D expenses 2007-2011 in US $B
Figure 5.16: AstraZeneca trend in R&D expenses Percentage of total revenue
Figure 5.17: Comparison of AstraZeneca SE R&D expenditure vs. top three & top five players average 2011
Figure 5.18: AstraZeneca productivity 2007-2011 (US $M)
Figure 5.19: AstraZeneca capital investment value 2007-2011 (US $M)
Figure 5.20: Strategic execution
CHAPTER 6. Company Profile of Bristol-Myers Squibb
Figure 6.1: Bristol-Myers Squibb revenue by business structure 2011
Figure 6.2: Lucintel triad - Bristol-Myers Squibb
Figure 6.3: Financial benchmarking of Bristol-Myers Squibb against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Bristol-Myers Squibb against Top five best
Figure 6.5: Global industry revenue trend Vs Bristol-Myers Squibb (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Bristol-Myers Squibb (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs. Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.8: European industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.9: APAC industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.10: ROW industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.11: North American market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.12: European market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 6.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 6.15: Bristol-Myers Squibb trend in R&D expenses 2007-2011 in US $B
Figure 6.16: Bristol-Myers Squibb trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Bristol-Myers Squibb SE R&D expenditure Vs top three & top five players average 2011
Figure 6.18: Bristol-Myers Squibb productivity: 2007-2011 in (US $M)
Figure 6.19: Bristol-Myers Squibb capital investment value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
CHAPTER 7. Company Profile of Novartis
Figure 7.1: Novartis revenue by business structure 2011
Figure 7.2: Lucintel triad – Novartis
Figure 7.3: Financial benchmarking of Novartis against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis l (2007-2011) in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.11: North American market share trend Vs Novartis (2007-2011) in (%)
Figure 7.12: European market share trend Vs Novartis l (2007-2011) in (%)
Figure 7.13: APAC market share trend Vs Novartis (2007-2011) in (%)
Figure 7.14: ROW market share trend Vs Novartis (2007-2011) in (%)
Figure 7.15: Novartis trend in R&D expenses 2007-2011 in US $B
Figure 7.16: Novartis trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis R&D expenditure vs top three & top five players average 2011
Figure 7.18: Novartis productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis capital investment value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
CHAPTER 8. Company Profile of Pfizer
Figure 8.1: Pfizer revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer
Figure 8.3: Financial benchmarking of Pfizer against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.15: Pfizer trend in R&D expenses 2007-2011 in US $B
Figure 8.16: Pfizer trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer capital investment value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
CHAPTER 9. Company Profile of Sanofi
Figure 9.1: Sanofi revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi
Figure 9.3: Financial benchmarking of Sanofi against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.15: Sanofi trend in R&D expenses 2007-2011 in US $B
Figure 9.16: Sanofi trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi capital investment value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for cardiovascular drug market
Figure 3.2: Global cardiovascular drug industry annual trend 2006-2011 (US $B)
Figure 3.3: Global cardiovascular drug industry regional trend 2006-2011 (US $B)
Figure 3.4: Global cardiovascular drug industry regional trend 2006-2011 (%)
Figure 3.5: Global cardiovascular drug industry segment trend 2006-2011 (US $B)
Figure 3.6: Global cardiovascular drug industry segment trend 2006-2011 (%)
Figure 3.7: Global cardiovascular drug industry opportunity by region
Figure 3.8: Global cardiovascular drug industry opportunity by segment
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five cardiovascular drug companies – financial benchmarking
Figure 4.2: Global top five cardiovascular drug companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
CHAPTER 5. Company Profile of AstraZeneca
Figure 5.1: AstraZeneca’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – AstraZeneca
Figure 5.3: Financial benchmarking AstraZeneca against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of AstraZeneca against Top Five best
Figure 5.5: Global industry revenue trend Vs AstraZeneca (2007-2011) in US $B
Figure 5.6: Global market share trend for AstraZeneca (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.12: European market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.15: AstraZeneca trend in R&D expenses 2007-2011 in US $B
Figure 5.16: AstraZeneca trend in R&D expenses Percentage of total revenue
Figure 5.17: Comparison of AstraZeneca SE R&D expenditure vs. top three & top five players average 2011
Figure 5.18: AstraZeneca productivity 2007-2011 (US $M)
Figure 5.19: AstraZeneca capital investment value 2007-2011 (US $M)
Figure 5.20: Strategic execution
CHAPTER 6. Company Profile of Bristol-Myers Squibb
Figure 6.1: Bristol-Myers Squibb revenue by business structure 2011
Figure 6.2: Lucintel triad - Bristol-Myers Squibb
Figure 6.3: Financial benchmarking of Bristol-Myers Squibb against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Bristol-Myers Squibb against Top five best
Figure 6.5: Global industry revenue trend Vs Bristol-Myers Squibb (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Bristol-Myers Squibb (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs. Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.8: European industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.9: APAC industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.10: ROW industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.11: North American market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.12: European market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 6.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 6.15: Bristol-Myers Squibb trend in R&D expenses 2007-2011 in US $B
Figure 6.16: Bristol-Myers Squibb trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Bristol-Myers Squibb SE R&D expenditure Vs top three & top five players average 2011
Figure 6.18: Bristol-Myers Squibb productivity: 2007-2011 in (US $M)
Figure 6.19: Bristol-Myers Squibb capital investment value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
CHAPTER 7. Company Profile of Novartis
Figure 7.1: Novartis revenue by business structure 2011
Figure 7.2: Lucintel triad – Novartis
Figure 7.3: Financial benchmarking of Novartis against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis l (2007-2011) in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.11: North American market share trend Vs Novartis (2007-2011) in (%)
Figure 7.12: European market share trend Vs Novartis l (2007-2011) in (%)
Figure 7.13: APAC market share trend Vs Novartis (2007-2011) in (%)
Figure 7.14: ROW market share trend Vs Novartis (2007-2011) in (%)
Figure 7.15: Novartis trend in R&D expenses 2007-2011 in US $B
Figure 7.16: Novartis trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis R&D expenditure vs top three & top five players average 2011
Figure 7.18: Novartis productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis capital investment value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
CHAPTER 8. Company Profile of Pfizer
Figure 8.1: Pfizer revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer
Figure 8.3: Financial benchmarking of Pfizer against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.15: Pfizer trend in R&D expenses 2007-2011 in US $B
Figure 8.16: Pfizer trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer capital investment value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
CHAPTER 9. Company Profile of Sanofi
Figure 9.1: Sanofi revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi
Figure 9.3: Financial benchmarking of Sanofi against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.15: Sanofi trend in R&D expenses 2007-2011 in US $B
Figure 9.16: Sanofi trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi capital investment value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
LIST OF TABLES
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global cardiovascular drug industry
Table 3.2: Relative market attractiveness by region
Table 3.3: Regional revenue growth rate
Table 3.4: Segment revenue growth rate
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global cardiovascular drug companies
Table 4.2: Key financial parameters for top five cardiovascular drug companies
Table 4.3: Regional revenue (US $M)
Table 4.4: Regional revenue (%)
Table 4.5: Competitors based on markets served
Table 4.6: Lucintel triad - Top five major players
CHAPTER 5. Company Profile of AstraZeneca
Table 5.1: Market served: AstraZeneca
Table 5.2: Lucintel triad – AstraZeneca
Table 5.3: Financial Benchmarking of AstraZeneca against best and against Top three and Top five industry players’ average
Table 5.4: Strategic execution – product positioning by segment
Table 5.5: Strategic execution – perceived customer value / quality
Table 5.6: Strategic execution – promotion / communications
Table 5.7: Strategic execution – product distribution by region
CHAPTER 6. Company Profile of Bristol-Myers Squibb
Table 6.1: Market served – Bristol-Myers Squibb
Table 6.2: Lucintel triad – Bristol-Myers Squibb
Table 6.3: Financial benchmarking of Bristol-Myers Squibb against best and against Top three and Top five industry players’ average
Table 6.4: Strategic execution – product positioning by segment
Table 6.5: Strategic execution – perceived customer value / quality
Table 6.6: Strategic execution – promotion / communications
Table 6.7: Strategic execution – product distribution by region
CHAPTER 7. Company Profile of Novartis
Table 7.1: Market served – Novartis
Table 7.2: Lucintel triad – Novartis
Table 7.3: Financial benchmarking of Novartis against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
CHAPTER 8. Company Profile of Pfizer
Table 8.1: Market served – Pfizer
Table 8.2: Lucintel triad – Pfizer
Table 8.3: Financial Benchmarking of Pfizer against best and against Top three and top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
CHAPTER 9. Company Profile of Sanofi
Table 9.1: Markets Served – Sanofi
Table 9.2: Lucintel triad – Sanofi
Table 9.3: Financial Benchmarking of Sanofi against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global cardiovascular drug industry
Table 3.2: Relative market attractiveness by region
Table 3.3: Regional revenue growth rate
Table 3.4: Segment revenue growth rate
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global cardiovascular drug companies
Table 4.2: Key financial parameters for top five cardiovascular drug companies
Table 4.3: Regional revenue (US $M)
Table 4.4: Regional revenue (%)
Table 4.5: Competitors based on markets served
Table 4.6: Lucintel triad - Top five major players
CHAPTER 5. Company Profile of AstraZeneca
Table 5.1: Market served: AstraZeneca
Table 5.2: Lucintel triad – AstraZeneca
Table 5.3: Financial Benchmarking of AstraZeneca against best and against Top three and Top five industry players’ average
Table 5.4: Strategic execution – product positioning by segment
Table 5.5: Strategic execution – perceived customer value / quality
Table 5.6: Strategic execution – promotion / communications
Table 5.7: Strategic execution – product distribution by region
CHAPTER 6. Company Profile of Bristol-Myers Squibb
Table 6.1: Market served – Bristol-Myers Squibb
Table 6.2: Lucintel triad – Bristol-Myers Squibb
Table 6.3: Financial benchmarking of Bristol-Myers Squibb against best and against Top three and Top five industry players’ average
Table 6.4: Strategic execution – product positioning by segment
Table 6.5: Strategic execution – perceived customer value / quality
Table 6.6: Strategic execution – promotion / communications
Table 6.7: Strategic execution – product distribution by region
CHAPTER 7. Company Profile of Novartis
Table 7.1: Market served – Novartis
Table 7.2: Lucintel triad – Novartis
Table 7.3: Financial benchmarking of Novartis against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
CHAPTER 8. Company Profile of Pfizer
Table 8.1: Market served – Pfizer
Table 8.2: Lucintel triad – Pfizer
Table 8.3: Financial Benchmarking of Pfizer against best and against Top three and top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
CHAPTER 9. Company Profile of Sanofi
Table 9.1: Markets Served – Sanofi
Table 9.2: Lucintel triad – Sanofi
Table 9.3: Financial Benchmarking of Sanofi against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
